C5 and paroxysmal nocturnal hemoglobinuria: Proximal complement inhibitors, such as Pegcetacoplan, prevent the activation of C3 complement protein, while terminal complement inhibitors, such as Eculizumab and Ravulizumab, target C5 activation and are considered the current treatment options for symptomatic PNH in many countries.